Therapeutic potential of implanted tissue-engineered bioartificial muscles delivering recombinant proteins to the sheep heart.
Tissue-engineered primary adult sheep muscle cells genetically engineered to express either rhVEGF or rhIGF-1 secreted the bioactive proteins locally in the sheep heart for at least 30 days.
Lu
Y
Y
Department of Pathology, Brown University School of Medicine and Miriam Hospital, Providence, RI 02906, USA.
Shansky
J
J
Del Tatto
M
M
Ferland
P
P
McGuire
S
S
Marszalkowski
J
J
Maish
M
M
Hopkins
R
R
Wang
X
X
Kosnik
P
P
Nackman
M
M
Lee
A
A
Creswick
B
B
Vandenburgh
H
H
D000818:Animals; D001672:Biocompatible Materials; D016228:Endothelial Growth Factors / Q000096:biosynthesis / Q000235:genetics; D015316:Genetic Therapy / Q000379:methods; D007150:Immunohistochemistry; D007334:Insulin-Like Growth Factor I / Q000096:biosynthesis / Q000235:genetics; D008222:Lymphokines / Q000096:biosynthesis / Q000235:genetics; D018482:Muscle, Skeletal / Q000166:cytology; D009132:Muscles / Q000166:cytology*; D009206:Myocardium / Q000166:cytology*; D018919:Neovascularization, Physiologic; D011994:Recombinant Proteins / Q000378:metabolism; D012756:Sheep; D013997:Time Factors; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D001672:Biocompatible Materials; D016228:Endothelial Growth Factors; D008222:Lymphokines; D011994:Recombinant Proteins; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D007334:Insulin-Like Growth Factor I